Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasm Metastasis 2Sarcoma, Synovial 1Sarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Neuroendocrine Tumors 1Neoplasms 1Mouth Neoplasms 1Lymphatic Metastasis 1Liposarcoma 1Leukemia, Myeloid, Acute 1Leiomyosarcoma 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Histiocytoma, Malignant Fibrous 1Gliosarcoma 1Glioblastoma 1Gallbladder Neoplasms 1Fallopian Tube Neoplasms 1Dermatofibrosarcoma 1Cholangiocarcinoma 1Carcinoma 1

Interventions

Magnetic Resonance Spectroscopy 49enzalutamide 46apalutamide 36Specimen Handling 34Androgen Antagonists 30Abiraterone Acetate 29Radiosurgery 27Prednisone 26darolutamide 25Docetaxel 23Pluvicto 22abiraterone 20Radiotherapy 19Biopsy 17Leuprolide 15relugolix 11gallium 68 PSMA-11 11acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 11Surveys and Questionnaires 11Radiation 112-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 11Standard of Care 10Nivolumab 10cabazitaxel 9X-Rays 9Triptorelin Pamoate 9bicalutamide 8Carboplatin 8pembrolizumab 7olaparib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms × peposertib × 90 days × Clear all
NCT04071236 2026-06-05

Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy

National Cancer Institute (NCI)

Phase 1/2 Recruiting
90 enrolled
Genitourinary

Lymphatic Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡